Arizona State Retirement System raised its stake in shares of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) by 0.4% during the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 26,201 shares of the specialty pharmaceutical company’s stock after buying an additional 100 shares during the period. Arizona State Retirement System owned approximately 0.05% of Supernus Pharmaceuticals worth $1,129,000 as of its most recent SEC filing.

A number of other institutional investors have also made changes to their positions in the stock. Meeder Asset Management Inc. raised its position in shares of Supernus Pharmaceuticals by 3,455.2% in the second quarter. Meeder Asset Management Inc. now owns 2,382 shares of the specialty pharmaceutical company’s stock valued at $103,000 after buying an additional 2,315 shares in the last quarter. Ameritas Investment Partners Inc. acquired a new position in shares of Supernus Pharmaceuticals during the first quarter valued at $127,000. Fortaleza Asset Management Inc. acquired a new position in shares of Supernus Pharmaceuticals during the first quarter valued at $160,000. State of Alaska Department of Revenue raised its position in shares of Supernus Pharmaceuticals by 3.2% in the first quarter. State of Alaska Department of Revenue now owns 5,530 shares of the specialty pharmaceutical company’s stock valued at $173,000 after buying an additional 170 shares in the last quarter. Finally, OppenheimerFunds Inc. acquired a new position in shares of Supernus Pharmaceuticals during the first quarter valued at $205,000. Institutional investors and hedge funds own 95.38% of the company’s stock.

Shares of Supernus Pharmaceuticals, Inc. (NASDAQ SUPN) opened at 44.75 on Tuesday. The firm has a 50-day moving average of $42.82 and a 200 day moving average of $35.43. The firm has a market capitalization of $2.27 billion, a price-to-earnings ratio of 22.58 and a beta of 1.31. Supernus Pharmaceuticals, Inc. has a 12-month low of $17.25 and a 12-month high of $46.55.

Supernus Pharmaceuticals (NASDAQ:SUPN) last released its quarterly earnings results on Wednesday, August 2nd. The specialty pharmaceutical company reported $0.32 earnings per share for the quarter, beating the consensus estimate of $0.24 by $0.08. The business had revenue of $75.83 million for the quarter, compared to analysts’ expectations of $68.54 million. Supernus Pharmaceuticals had a net margin of 41.10% and a return on equity of 30.73%. On average, equities research analysts expect that Supernus Pharmaceuticals, Inc. will post $1.04 earnings per share for the current year.

ILLEGAL ACTIVITY NOTICE: This story was posted by Watch List News and is owned by of Watch List News. If you are viewing this story on another publication, it was illegally stolen and republished in violation of U.S. & international trademark & copyright law. The correct version of this story can be viewed at https://www.watchlistnews.com/arizona-state-retirement-system-has-1-13-million-position-in-supernus-pharmaceuticals-inc-supn/1528973.html.

SUPN has been the topic of several analyst reports. Zacks Investment Research upgraded shares of Supernus Pharmaceuticals from a “hold” rating to a “buy” rating and set a $49.00 price objective on the stock in a report on Thursday, July 13th. Cantor Fitzgerald increased their price objective on shares of Supernus Pharmaceuticals from $34.00 to $49.00 and gave the company a “buy” rating in a report on Wednesday, July 5th. Jefferies Group LLC increased their price objective on shares of Supernus Pharmaceuticals from $45.00 to $51.00 and gave the company a “buy” rating in a report on Wednesday, June 28th. Stifel Nicolaus restated a “buy” rating and issued a $47.00 price objective (up from $36.00) on shares of Supernus Pharmaceuticals in a report on Tuesday, July 18th. Finally, BidaskClub lowered shares of Supernus Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a report on Tuesday, July 25th. Three analysts have rated the stock with a hold rating and five have given a buy rating to the company. The stock presently has an average rating of “Buy” and an average target price of $48.43.

In related news, VP Padmanabh P. Bhatt sold 3,735 shares of Supernus Pharmaceuticals stock in a transaction on Wednesday, July 12th. The shares were sold at an average price of $44.90, for a total value of $167,701.50. Following the sale, the vice president now owns 21,209 shares in the company, valued at $952,284.10. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, VP Padmanabh P. Bhatt sold 2,556 shares of Supernus Pharmaceuticals stock in a transaction on Friday, June 23rd. The shares were sold at an average price of $44.90, for a total transaction of $114,764.40. Following the completion of the sale, the vice president now owns 24,944 shares in the company, valued at approximately $1,119,985.60. The disclosure for this sale can be found here. In the last quarter, insiders sold 20,000 shares of company stock worth $848,824. 6.70% of the stock is currently owned by company insiders.

Supernus Pharmaceuticals Company Profile

Supernus Pharmaceuticals, Inc is a pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases. The Company offers Oxtellar XR (extended-release oxcarbazepine) and Trokendi XR (extended-release topiramate), its two treatments for patients with epilepsy.

Want to see what other hedge funds are holding SUPN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN).

Institutional Ownership by Quarter for Supernus Pharmaceuticals (NASDAQ:SUPN)

Receive News & Ratings for Supernus Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Supernus Pharmaceuticals Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.